Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)

NCT03536143 is registered in ClinicalTrials.gov with Krystal Biotech, Inc. as lead sponsor.

NCT NCT03536143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Lead sponsor
Krystal Biotech, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 6, 2018
Completion date
November 1, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa